ABCDABCD mMRC < 2 CAT <10 mMRC >2 CAT >10 43214321 1010 >2>2 RISK GOLD RISK Exacerbation TypeCharatteristicSpirometric classification Exacerbation Per.

Slides:

Advertisements

Similar presentations

Chapter 1 The Study of Body Function Image PowerPoint

Advertisements

© Global Initiative for Chronic Obstructive Lung Disease

© Global Initiative for Chronic Obstructive Lung Disease

© 2014 Global Initiative for Chronic Obstructive Lung Disease

New Guidelines for COPD They keep changing. . . are you up to speed?

Look at what we can read!. am saw so soon them walk.

We will resume in: 25 Minutes.

Number Factors and Multiples Saturday, 09 September 2006 ©RSH.

Turbo Training Aerobic conditioning.

Planning, COPD Hot Topics and CSA preparation Ruth Gooch 11/1/12.

GOLD Clasification Antonio Anzueto MD Professor Medicine University of Texas.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

Figure Figure 18-1 part 1 Figure 18-1 part 2.

COPD Alison Boland StR Respiratory medicine. Aims & Objectives Overview of COPD Recap basic knowledge Update on COPD Know when to use nebulisers and home.

Chronic obstructive pulmonary disease (COPD) Professor Bill MacNee

Sublobar Resection and Intraoperative Brachytherapy for Lung Cancer: ACOSOG Update Rodney J. Landreneau, MD Professor of Surgery The Heart Lung and Esophageal.

© 2013 Global Initiative for Chronic Obstructive Lung Disease

1 PULMONARY REHABILITATION Asthma/COPD Study Day 11/12/13 Fran Butler Respiratory Physiotherapist.

“How your approach in COPD might change in 2012”

GOLD Website Address

COPD AS Systemic disease BY Dr/Sami EL-Dahdouh (MD) Lecturer of Pulmonary & Critical care Faculty of Medicine, Menofia University.

COPD update Prof. Ramadan Nafae By

Matt Wong + Sheila Murphy Dec 13 th  AKT MINI EXAM  NICE – COPD GUIDELINES  BTS ASTHMA GUIDELINES  INHALER TECHNIQUE  QOF  SPIROMETRY  CSA.

Update on COPD Management

Asthma vs COPD Asthma COPD -FEV1 improves by 12% or more with

GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.

ASSITANT PROFESSOR EAST MEDICAL WARD MAYO HOSPITAL,LAHORE

Breathless Patient Aaqid Akram MBChB (2013) Clinical Education Fellow.

© IPCRG 2007 COPD -Management of stable disease WONCA meeting Istanbul October 2015 Svein Høegh Henrichsen Oslo, Norway.

Asthma vs COPD Asthma COPD -FEV1 improves by 12% or more with

Severe breathlessness

Picking up the Clues Bert the breathless patient….. March 2015 GL/XBR/0315/0356.

Picking up the Clues Bert the breathless patient….. Date of Preparation: Mar 2015 GL/XBR/0315/0356.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.

Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.

Chronic obstructive respiratory disease What’s new, and what isn’t Jaime C Sousa (PT) Ioanna Tsiligianni (GR) Anders Østrem (NO), IPCRG.

GOLD 2017 major revision: Summary of key changes

Pulmonary Center of Excellence

Chronic Obstructive Pulmonary Disease(COPD)

COPD – Primary Care Update

Thank you for viewing this presentation.

Management of Stable COPD

COPD Tutoring – Part 1 By Alaina Darby.

COPD PATHWAY AND PRESCRIBING POLICY IN LAMA options (stop SAMA):

COPD Report 5 Coles Lane, Oakington, Cambridge, CB24 3BA.

Alan Kaplan MD CCFP(EM) FCFP Family Physician Airways Group of Canada

Reduced Quality of Life

COPD By Alaina Darby.

Copyright © 2015 by the American Osteopathic Association.

Assessing COPD in Primary Care

Treatment Strategies in Mild to Moderate COPD

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

COPD: One Patient’s Journey

Highlights From the Inaugural COPD7USA Conference: Focus on Treatment Challenges in COPD.

REMOTE PULMONARY REHABILITATION A Model for Delivery

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

Volume 153, Issue 4, Pages (April 2018)

Volume 152, Issue 6, Pages (December 2017)

Long-Acting Agents in Severe COPD

Diagnosi della BPCO 1.

Management of Chronic Stable COPD

And WHY does it matter which label?

Prescribing Update - Respiratory July 2019

Plots showing baseline correlation between the modified Medical Research Council (mMRC) dyspnoea scale, Baseline Dyspnoea Index (BDI), COPD Assessment.

COPD Guidelines: A Review of the 2018 GOLD Report

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) ABCD scheme for classifying patients with COPD with separate appraisal of air-flow limitation.

Presentation transcript:

ABCDABCD mMRC < 2 CAT <10 mMRC >2 CAT > >2>2 RISK GOLD RISK Exacerbation TypeCharatteristicSpirometric classification Exacerbation Per year CAT A Low risk, low symptomsGOLD1 / GOLD2< 1< 10 B Low risk, high symptomsGOLD1 / GOLD2< 1> 10 C High risk, low symptomsGOLD3 / GOLD4+2< 10 D High risk, High symptomsGOLD3 / GOLD4+2> 10 Downloaded from © Progetto LIBRAwww.goldcopd.it

TypeFirst choiceSecond choiceAlternative choice A SABA or SAMA prnSABA and SAMA LABA or LAMA Theophylline B LABA or LAMALABA and LAMATheophylline SABA and/or SAMA C ICS/LABA or LAMALABA and LAMA ICS and LAMA Theophylline SABA and/or SAMA Consider PDE4-inh* D ICS/LABA or LAMAICS/LABA and LAMA ICS/LABA and PDE4-inh* LAMA and PDE4-inh Theophylline SABA and/or SAMA Carbocysteine ABCDABCD mMRC < 2 CAT <10 mMRC >2 CAT > >2>2 RISK GOLD RISK Exacerbation Downloaded from - © Progetto LIBRAwww.goldcopd.it

Downloaded from - © Progetto LIBRAwww.goldcopd.it

Figure 2.3: RISK IN COPD: Placebo-limb data from TORCH 143*, Uplift 142† and Eclipse 131≠ GOLD spirometric level Exacerbations (per year) *†≠ Hospitalizations (per year) * ≠ 3-year Mortality *† GOLD 1: Mild? ? ? GOLD 2: Moderate % *† GOLD 3: Severe % * GOLD 4: Very severe1.2 – % * Downloaded from - © Progetto LIBRAwww.goldcopd.it

Table 2.3: Modified Medical Research Council Questionnaire for Assessing the Severity of Breathlessness PLEASE TICK IN THE BOX THAT APPLIES TO YOU (ONE BOX ONLY) mMRC Grade 0. I only get breathless with strenuous exercise. mMRC Grade 1. I get short of breath when hurrying on the level or walking up a slight hill. mMRC Grade 2. I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level. mMRC Grade 3. I stop for breath after walking about 100 meters or after a few minutes on the level. mMRC Grade 4. I am too breathless to leave the house or I am breathless when dressing or undressing. Downloaded from - © Progetto LIBRAwww.goldcopd.i